Clinical Trial Update: A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SAGE-217 in participants with Parkinson's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SAGE-217 (zuranolone)

Snippet

Sponsor: Biogen | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-11-23